# US 2008/0187572 A1 · Matrix Metalloproteinase Inhibitors of Tgfb-Induced Subcapsular Cataract Formation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187572 A1
- Document ID: US20080187572A1
- Status: Published application
- Kind: A1
- Application number: 11/912,729
- Filed: 2006-04-28
- Published: 2008-08-07
- Earliest claimed: 2005-04-28
- Assignees: McMaster University
- Inventors: Judith West-Mays
- Web page: https://patentgrep.com/patent/US20080187572A1

## CPC

- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 27/12: for cataracts
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides novel methods and compositions for the treatment and/or prevention of cataracts. A composition that inhibits destabilization of E-cadherin is administered. Preferably the composition comprises a matrix metalloproteinase inhibitor.

## Claims

### Claim 1

A method of treating or preventing cataract, said method comprising administering to a subject in need of such treatment, a therapeutically effective amount of an agent that inhibits E-cadherin destabilization.

### Claim 2 (depends on 1)

A method according to claim 1 wherein cataract is a subcapsular cataract.

### Claim 3 (depends on 2)

A method according to claim 2 wherein cataract is an anterior subcapsular cataract.

### Claim 4 (depends on 1)

A method according to claim 1 wherein the agent is a matrix metalloproteinase inhibitor (MMPI).

### Claim 5 (depends on 4)

A method according to claim 4 wherein the MMPI is a broad range MMPI.

### Claim 6 (depends on 4)

A method according to claim 4 wherein the MMPI is selected from the group consisting of: ((2R)-[(4-Biphenylylsulfonyl)amino]-N-hydroxyl-3-phenylpropionamide); actinonin (3-[[1-[[2-(hydroxymethyl)-1-pyrrolidinyl]carbamoyl]-octano-hydroxamic acid); bromocyclic-adenosine monophosphate; N-chlorotaurine; BATIMISTAT (BB-94); CT1166 (N1 {N-[2-(morpholinosulphonylamino)-ethyl]-3-cyclohexyl-2-(S)-propanamidyl}-N4-hydroxy-2-(R)-[3-(4-methylphenyl)propyl]-succinamide); estramustine (estradiol-3-bis(2-chloroethyl)carbamat-e); eicosa-pentaenoic acid; MARIMASTAT (BB-2516); matlystatin-B; peptidyl hydroxamic acids; N-phosphonalkyl dipeptides; protocatechuic aldehyde (3,4-dihydroxybenzaldehyde); Ro-31-7467 (2-[(5-bromo-2,3-dihydro-6-hydroxy-1,3-dioxo-1H-benz[de]isoquinol-in-2-yl)methyl](hydroxy)-[phosphinyl]-N-(2-oxo-3-azacyclotridecanyl)-4-met-hylvaleramide); tetracyclines; 1,10-phenanthroline (o-phenanthroline[4-(N-hydroxyamino)-2R-isobutyl-3S-(thiopen-2-ylthiomethyl)-succinyl]-L-p-henylalanine-N-methylamidecarboxyalkylamino-based compounds; chelators (EDTA, cysteine, acetylcysteine, D-penicillamine, and gold salts); bis(dioxopiperzaine); NEOVASTAT; KB-R7785; ILOMASTAT; RPR-122818; SOLIMASTAT; BB-1101; BB-2983; BB-3644; BMS-275291; D-1927, D-5410; CH-5902, CH-138; CMT-3; DERMOSTAT; DAC-MMPI; RS-1130830 and RS-113-080; GM-1339; GI-155704A; ONO-4817; AG-3433, AG-3088, PRINOMASTAT; CP-544439; POL-641: SC-964; SD-2590; PNU-142769; SU-5402; PGE-2946979, PGE-4304887; fibrolase-conjugate; EF-13; S-3304; CGS-25015 and CGS-27023A; XR-168; RO1130830; D-9120; BB-2827; BB-1101 (2S-allyl-N1-hydroxy-3R-isobutyl-N4-(1S-methylcarbamoyl-2-phenylethyl)-su-ccinamide), BB-2983, solimastat (N′-[2,2-Dimethyl-[1(S)—[N-(2-pyridyl)carba-moyl]propyl]-N4-hydroxy-2(R)-isobutyl-3(S)-methoxysuccinamide), N4-hydroxy-N1-[2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpr-opyl)-3-[(2-thienylthio)methyl]-, [2R-[1 (S*),2R*,3 S*]]-[CAS]), rebimastat (L-Valinamide, N—((2S)-2-mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-[CAS]); PS-508; CH-715; nimesulide (Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-[CAS]-), hexahydro-2-[2(R)-[1(RS)-(hydroxycarbamoyl)-4-phenylbutyl]nonanoyl]-N-(-2,2,6,6-etramethyl-4-piperidinyl)-3(S)-pyridazine carboxamide, Cipemastat (1-Piperidinebutanamide, .beta.-(cyclopentylmethyl)-N-hydroxy-Gamma-oxo-A-lpha-[(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-,(AlphaR,.beta.R-)-[CAS]), 5-(4′-biphenyl)-5-[N-(4-nitrophenyl)piperazinyl]barbituric acid, 6-methoxy-1,2,3,4-tetrahydro-norharman-1-carboxylic acid, Ro-31-4724 (L-Alanine, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-le-ucyl-, ethyl ester[CAS]), N-hydroxy-2,2-dimethyl-4-((4-(4-pyridinyloxy)phe-nyl)sulfonyl)-, (3R)-[CAS]), PNU-142769 (2H-Isoindole-2-butanamide, 1,3-dihydro-N-hydroxy-Alpha-[(3S)-3-(2-methylpropyl)-2-oxo-1-(2-phenyleth-yl)-3-pyrrolidinyl]-1,3-dioxo-, (AlphaR)-[CAS]), (S)-1-[2-[[[(4,5-Dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)amino]-carbonyl]amino]-1-oxo-3-(pentafluoro-phenyl)propyl]-4-(2-pyridinyl)piperazine, SC-77964, PNU-171829, N-hydroxy-2(R)-[(4-methoxybenzene-sulfonyl)(4-picolyl)amino]-2-(2-tetrahy-drofuranyl)-acetamide, L-758354 ((1,1′-Biphenyl)-4-hexanoic acid, Alpha-butyl-Gamma-(((2,2-dimethyl-1-((methylamino)carbonyl)propyl)amino)c-arbonyl)-4′-fluoro-, (AlphaS-(AlphaR*,GammaS*(R*)))-[CAS]); antibodies; and analogues or derivatives thereof.

### Claim 7 (depends on 5)

A method according to claim 5 wherein the MMPI is selected from the group consisting of an MMP-2 inhibitor, an MMP-9 inhibitor and an MMP-2/9 inhibitor.

### Claim 8 (depends on 4)

A method according to claim 4 wherein the inhibitor is Ilomastat (GM6001).

### Claim 9 (depends on 4)

A method according to claim 4 wherein the inhibitor is ((2R)-[(4-Biphenylylsulfonyl)amino]-N-hydroxyl-3-phenylpropionamide).

### Claim 10 (depends on 1)

The method of claim 1 wherein the inhibitor is locally administered.

### Claim 11 (depends on 9)

The method of claim 9 wherein the inhibitor is delivered via a controlled release device.

### Claim 12 (depends on 10)

The method of claim 10 wherein the controlled release device is implanted in the eye.

### Claim 13 (depends on 9)

The method of claim 9 wherein the inhibitor is delivered by injection.

### Claim 14 (depends on 9)

The method of claim 9 wherein the inhibitor is administered as an ophthalmic solution, gel or cream.

### Claim 15 (depends on 1)

The method of claim 1 wherein the inhibitor is administered in a dose range of about 0.1 μg/ml to about 500 μg/ml.

### Claim 16 (depends on 15)

The method of claim 15 wherein the inhibitor is administered in a dose range of about 1 μg/ml to 100 μg/ml.

### Claim 17 (depends on 16)

The method of claim 16 wherein the inhibitor is administered in a dose range of about 5 μg/ml to 25 μg/ml.

### Claim 18 (depends on 1)

The method of claim 1 wherein the inhibitor is administered in combination with at least one additional MMP inhibitor.

### Claim 19 (depends on 1)

The method of claim 1 wherein the inhibitor is administered with another pharmacologically active agent.

### Claim 20

A composition for the treatment or prevention of cataract comprising an MMPI and a pharmaceutically acceptable carrier.

### Claim 21 (depends on 21)

A composition according to claim 21, wherein the MMPI is wherein the MMPI is selected from the group consisting of: ((2R)-[(4-Biphenylylsulfonyl)amino]-N-hydroxyl-3-phenylpropionamide); actinonin (3-[[1-[[2-(hydroxymethyl)-1-pyrrolidinyl]carbamoyl]-octano-hydroxamic acid); bromocyclic-adenosine monophosphate; N-chlorotaurine; BATIMISTAT (BB-94); CT1166 (N1 {N-[2-(morpholinosulphonylamino)-ethyl]-3-cyclohexyl-2-(S)-propanamidyl}-N4-hydroxy-2-(R)-[3-(4-methylphenyl)propyl]-succinamide); estramustine (estradiol-3-bis(2-chloroethyl)carbamat-e); eicosa-pentaenoic acid; MARIMASTAT (BB-2516); matlystatin-B; peptidyl hydroxamic acids; N-phosphonalkyl dipeptides; protocatechuic aldehyde (3,4-dihydroxybenzaldehyde); Ro-31-7467 (2-[(5-bromo-2,3-dihydro-6-hydroxy-1,3-dioxo-1H-benz[de]isoquinol-in-2-yl)methyl](hydroxy)-[phosphinyl]-N-(2-oxo-3-azacyclotridecanyl)-4-met-hylvaleramide); tetracyclines; 1,10-phenanthroline (o-phenanthroline[4-(N-hydroxyamino)-2R-isobutyl-3S-(thiopen-2-ylthiomethyl)-succinyl]-L-p-henylalanine-N-methylamidecarboxyalkylamino-based compounds; chelators (EDTA, cysteine, acetylcysteine, D-penicillamine, and gold salts); bis(dioxopiperzaine); NEOVASTAT; KB-R7785; ILOMASTAT; RPR-122818; SOLIMASTAT; BB-1101; BB-2983; BB-3644; BMS-275291; D-1927, D-5410; CH-5902, CH-138; CMT-3; DERMOSTAT; DAC-MMPI; RS-1130830 and RS-113-080; GM-1339; GI-155704A; ONO-4817; AG-3433, AG-3088, PRINOMASTAT; CP-544439; POL-641: SC-964; SD-2590; PNU-142769; SU-5402; PGE-2946979, PGE-4304887; fibrolase-conjugate; EF-13; S-3304; CGS-25015 and CGS-27023A; XR-168; RO1130830; D-9120; BB-2827; BB-1101 (2S-allyl-N1-hydroxy-3R-isobutyl-N4-(1S-methylcarbamoyl-2-phenylethyl)-su-ccinamide), BB-2983, solimastat (N′-[2,2-Dimethyl-[(S)-[N-(2-pyridyl)carba-moyl]propyl]-N4-hydroxy-2(R)-isobutyl-3(S)-methoxysuccinamide), N4-hydroxy-N1-[2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpr-opyl)-3-[(2-thienylthio)methyl]-, [2R-[1 (S*),2R*,3S*]]-[CAS]), rebimastat (L-Valinamide, N-((2S)-2-mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-[CAS]); PS-508; CH-715; nimesulide (Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-[CAS]-), hexahydro-2-[2(R)-[1(RS)-(hydroxycarbamoyl)-4-phenylbutyl]nonanoyl]-N-(-2,2,6,6-etramethyl-4-piperidinyl)-3(S)-pyridazine carboxamide, Cipemastat (1-Piperidinebutanamide, .beta.-(cyclopentylmethyl)-N-hydroxy-Gamma-oxo-A-lpha-[(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-,(AlphaR,.beta.R—)-[CAS]), 5-(4′-biphenyl)-5-[N-(4-nitrophenyl)piperazinyl]barbituric acid, 6-methoxy-1,2,3,4-tetrahydro-norharman-1-carboxylic acid, Ro-31-4724 (L-Alanine, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-le-ucyl-, ethyl ester[CAS]), N-hydroxy-2,2-dimethyl-4-((4-(4-pyridinyloxy)phe-nyl)sulfonyl)-, (3R)-[CAS]), PNU-142769 (2H-Isoindole-2-butanamide, 1,3-dihydro-N-hydroxy-Alpha-[(3S)-3-(2-methylpropyl)-2-oxo-1-(2-phenyleth-yl)-3-pyrrolidinyl]-1,3-dioxo-, (AlphaR)-[CAS]), (S)-1-[2-[[[(4,5-Dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)amino]-carbonyl]amino]-1-oxo-3-(pentafluoro-phenyl)propyl]-4-(2-pyridinyl)piperazine, SC-77964, PNU-171829, N-hydroxy-2(R)-[(4-methoxybenzene-sulfonyl)(4-picolyl)amino]-2-(2-tetrahy-drofuranyl)-acetamide, L-758354 ((1,1′-Biphenyl)-4-hexanoic acid, Alpha-butyl-Gamma-(((2,2-dimethyl-1-((methylamino)carbonyl)propyl)amino)c-arbonyl)-4′-fluoro-, (AlphaS-(AlphaR*,GammaS*(R*)))-[CAS]); antibodies; and analogues or derivatives thereof.

### Claim 22 (depends on 21)

A composition according to claim 21 wherein the MMPI is selected from the group consisting of an MMP-2 inhibitor, an MMP-9 inhibitor and an MMP-2/9 inhibitor.

### Claim 23 (depends on 21)

A composition according to claim 21 wherein the inhibitor is Ilomastat (GM6001).

### Claim 24 (depends on 21)

A composition according to claim 21 wherein the inhibitor is ((2R)-[(4-Biphenylylsulfonyl)amino]-N-hydroxyl-3-phenylpropionamide).

### Claim at position 25

-28. (canceled)

### Claim 29

A delivery device for the administration of a matrix metalloproteinase inhibitor to a region of an eye of a patient.

### Claim 30 (depends on 29)

A delivery device according to claim 29 wherein the device is a contact lens.

### Claim 31 (depends on 29)

A delivery device according to claim 29 wherein the device is an intra-ocular lens.
